Complete Response to Trastuzumab-Deruxtecan (Enhertu, T-DXd) in HER2-Positive Stage IVB Uterine Carcinosarcoma

Authors

Michael Kim
Amma Asare
Jamie L Dockery
Nadia Hameed
Travis T Sims

Language

English

Publication Date

8-1-2025

Journal

Gynecologic Oncology Reports

DOI

10.1016/j.gore.2025.101797

PMID

40687920

PMCID

PMC12271612

PubMedCentral® Posted Date

6-25-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Objectives: To report a case of complete response to trastuzumab-deruxtecan (T-DXd) in a patient with HER2-positive stage IVB uterine carcinosarcoma, and to contextualize this within evolving therapy for HER2-positive gynecologic malignancies.

Methods: We present the clinical course of a 62-year-old woman with a history of multiple prior malignancies, diagnosed with stage IVB uterine carcinosarcoma exhibiting HER2 overexpression. Following optimal cytoreductive surgery and first-line carboplatin, paclitaxel, and trastuzumab, the patient developed platinum-resistant recurrence. She was subsequently treated with T-DXd, and received serial imaging and clinical monitoring.

Results: The patient achieved a partial response by cycle 4 of T-DXd, with subsequent scans demonstrating a complete response with no evidence of disease. She has successfully completed 21 cycles of T-DXd with minimal toxicity, aside from a reversible acute kidney injury and a small pleural effusion, both resolving without sequelae. The patient remains asymptomatic and continues therapy without any cardiopulmonary complications.

Conclusions: This case highlights the efficacy of T-DXd for HER2-positive, platinum-resistant uterine carcinosarcoma, even when previously treated with Trastuzumab. Highly durable, complete response with manageable toxicity was achieved, underscoring the promise of T-DXd.

Keywords

Trastuzumab-deruxtecan, Enhertu, T-DXd, Uterine carcinosarcoma, HER2, NED

Published Open-Access

yes

Recommended Citation

Kim, Michael; Asare, Amma; Dockery, Jamie L; et al., "Complete Response to Trastuzumab-Deruxtecan (Enhertu, T-DXd) in HER2-Positive Stage IVB Uterine Carcinosarcoma" (2025). Faculty, Staff and Student Publications. 5985.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5985